You may be eligible for a refund from an $85M Settlement if you purchased certain named generic pharmaceutical drugs directly from certain pharmaceutical manufacturers from May 1, 2009 through December 31, 2019. The complete list of Named Generic Drugs and Defendants are included.
Settlement Summary: Two proposed settlements have been reached in a class action lawsuit which alleges that Sun Pharmaceutical Industries, Inc. and its affiliates Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc. violated the federal antitrust laws by conspiring with other generic drug manufacturers to fix, maintain, and stabilize prices, rig bids, and engage in market and customer allocations of certain generic drugs, causing direct purchasers of the Named Generic Drugs to pay more than they should have. The Settling Defendants deny liability as alleged in the Lawsuit. The Court has not decided who is right. The proposed Settlements do not resolve any of the claims of the Settlement Class against the remaining Defendants. The lawsuit against the remaining Defendants is ongoing.
Eligible Class Members: The Court certified a Settlement Class that includes all persons or entities, and their successors and assigns, that directly purchased one or more of the named generic drugs from one or more Defendants in the United States and its territories and possessions, at any time during the period from May 1, 2009 through December 31, 2019. Excluded from the Settlement Class are Defendants and their present and former officers, directors, management, employees, subsidiaries, or affiliates, judicial officers and their personnel, and all governmental entities.
- Current Settlement Total: $85,000,000
- Defendants: Sun Pharmaceutical Industries, Inc., Caraco Pharmaceutical Laboratories, Ltd., Mutual Pharmaceutical Company, Inc., and URL Pharma, Inc., and Taro Pharmaceuticals U.S.A., Inc.
- Covered Period: May 1, 2009 – December 31, 2019
- Filing Deadline: TBD
- Contact DSG
View the class action summary in a PDF.